Volume 26, Number 4—April 2020
Synopsis
Severe Fever with Thrombocytopenia Syndrome, Japan, 2013–2017
Yusuke Kobayashi1, Hirofumi Kato, Takuya Yamagishi, Tomoe Shimada, Tamano Matsui, Tomoki Yoshikawa, Takeshi Kurosu, Masayuki Shimojima, Shigeru Morikawa2, Hideki Hasegawa, Masayuki Saijo, Kazunori Oishi3
, and SFTS Epidemiological Research Group Japan
, and SFTS Epidemiological Research Group Japan
Table 2
Multivariable analysis of prognostic factors for 133 patients with severe fever with thrombocytopenia syndrome, Japan, March 2013–October 2017*
| Variable | Univariable |
Multivariable |
|||
|---|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | ||
| Age | NA | 0.015 | 1.07 (0.98–1.16) | 0.115 | |
| Malignant tumor | 6.13 (1.45–26.04) | 0.006 | 20.83 (1.32–327.70) | 0.031 | |
| Disorientation | 1.58 (0.71–3.52) | 0.259 | 1.37 (0.30–6.35) | 0.687 | |
| Tremor | 8.60 (1.57–47.04) | 0.004 | 17.37 (1.26–239.39) | 0.033 | |
| Platelet | NA | 0.661 | 1.38 (1.07–1.78) | 0.014 | |
| Albumin | NA | 0.791 | 0.99 (0.15–6.62) | 0.994 | |
| ALT | NA | 0.015 | 1.01 (1.00–1.02) | 0.371 | |
| LDH | NA | 0.012 | 1.00 (1.00–1.00) | 0.378 | |
| CK | NA | 0.591 | 1.00 (1.00–1.00) | 0.842 | |
| APTT | NA | 0.007 | 1.06 (0.97–1.16) | 0.215 | |
*ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; CK, creatine kinase; LDH, lactate dehydrogenase; NA, not applicable; OR, odds ratio.
1Current affiliation: Saitama Prefectural Government, Saitama, Japan.
2Current affiliation: Okayama University of Science, Ehime, Japan.
3Current affiliation: Toyama Institute of Health, Toyama, Japan.
4Group members are listed at the end of the article.
Page created: March 17, 2020
Page updated: August 10, 2020
Page reviewed: August 10, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.